Evercore ISI Lowers Moderna (NASDAQ:MRNA) Price Target to $50.00

Moderna (NASDAQ:MRNA - Free Report) had its price target reduced by Evercore ISI from $60.00 to $50.00 in a research report sent to investors on Monday morning,Benzinga reports. They currently have an in-line rating on the stock.

Other analysts have also issued research reports about the company. Berenberg Bank boosted their target price on Moderna from $33.00 to $42.00 and gave the company a "hold" rating in a research report on Thursday, January 16th. Bank of America reissued an "underperform" rating and set a $41.00 target price on shares of Moderna in a research note on Tuesday, December 10th. JPMorgan Chase & Co. lowered their target price on Moderna from $59.00 to $45.00 and set an "underweight" rating for the company in a report on Tuesday, November 26th. UBS Group cut their price target on shares of Moderna from $108.00 to $96.00 and set a "buy" rating on the stock in a research note on Wednesday, January 8th. Finally, HSBC raised shares of Moderna from a "hold" rating to a "buy" rating and set a $58.00 price objective for the company in a research note on Monday, November 18th. Four research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, Moderna has a consensus rating of "Hold" and a consensus price target of $67.26.

Moderna Trading Down 3.9 %

Shares of NASDAQ MRNA traded down $1.62 during mid-day trading on Monday, reaching $39.42. 6,504,183 shares of the company's stock were exchanged, compared to its average volume of 12,593,684. The firm has a market capitalization of $15.17 billion, a price-to-earnings ratio of -6.77 and a beta of 1.60. Moderna has a 52-week low of $31.94 and a 52-week high of $170.47. The company's 50-day moving average is $40.87 and its 200-day moving average is $62.03. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.20 and a current ratio of 4.39.

Moderna (NASDAQ:MRNA - Get Free Report) last announced its earnings results on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, topping the consensus estimate of ($1.89) by $1.92. The company had revenue of $1.90 billion during the quarter, compared to analyst estimates of $1.25 billion. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. Moderna's revenue was up 3.8% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.39) earnings per share. Analysts expect that Moderna will post -9.26 EPS for the current fiscal year.

Insider Transactions at Moderna

In related news, insider Shannon Thyme Klinger sold 1,418 shares of Moderna stock in a transaction on Friday, November 29th. The shares were sold at an average price of $42.79, for a total transaction of $60,676.22. Following the sale, the insider now directly owns 19,717 shares in the company, valued at $843,690.43. This trade represents a 6.71 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In the last ninety days, insiders sold 2,664 shares of company stock valued at $115,210. 15.70% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Moderna

Several hedge funds have recently made changes to their positions in MRNA. Blue Trust Inc. raised its holdings in shares of Moderna by 365.6% in the third quarter. Blue Trust Inc. now owns 731 shares of the company's stock valued at $49,000 after buying an additional 574 shares during the last quarter. Wilmington Savings Fund Society FSB boosted its holdings in Moderna by 295.0% during the fourth quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company's stock worth $33,000 after buying an additional 587 shares in the last quarter. Venturi Wealth Management LLC boosted its stake in shares of Moderna by 286.2% during the 4th quarter. Venturi Wealth Management LLC now owns 896 shares of the company's stock worth $37,000 after acquiring an additional 664 shares in the last quarter. Larson Financial Group LLC grew its holdings in Moderna by 53.5% in the third quarter. Larson Financial Group LLC now owns 910 shares of the company's stock valued at $61,000 after purchasing an additional 317 shares during the last quarter. Finally, Rakuten Securities Inc. increased its position in shares of Moderna by 477.3% in the third quarter. Rakuten Securities Inc. now owns 941 shares of the company's stock valued at $63,000 after buying an additional 778 shares in the last quarter. Hedge funds and other institutional investors own 75.33% of the company's stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.